000136367 001__ 136367
000136367 005__ 20240321220045.0
000136367 0247_ $$2doi$$a10.3233/JAD-2011-0025
000136367 0247_ $$2pmid$$apmid:21971473
000136367 0247_ $$2ISSN$$a1387-2877
000136367 0247_ $$2ISSN$$a1875-8908
000136367 037__ $$aDZNE-2020-02689
000136367 041__ $$aEnglish
000136367 082__ $$a610
000136367 1001_ $$0P:(DE-HGF)0$$aFörster, Stefan$$b0$$eCorresponding author
000136367 245__ $$aEffects of a 6-month cognitive intervention on brain metabolism in patients with amnestic MCI and mild Alzheimer's disease.
000136367 260__ $$aAmsterdam$$bIOS Press$$c2011
000136367 264_1 $$2Crossref$$3print$$bIOS Press$$c2011-10-04
000136367 3367_ $$2DRIVER$$aarticle
000136367 3367_ $$2DataCite$$aOutput Types/Journal article
000136367 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1710946161_2064
000136367 3367_ $$2BibTeX$$aARTICLE
000136367 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136367 3367_ $$00$$2EndNote$$aJournal Article
000136367 520__ $$aThe effect of cognitive intervention on brain metabolism in AD is largely unexplored. Therefore, we aimed to investigate cognitive parameters and 18FDG PET to test for effects of a cognitive intervention in patients with aMCI or mild AD. Patients with aMCI (N = 24) or mild AD (N = 15) were randomly assigned either to cognitive intervention groups (IGs), receiving weekly sessions of group-based multicomponent cognitive intervention, or active control groups (CGs), receiving pencil-paper exercises for self-study. We obtained resting-state FDG-PET scans and neuropsychological testing at baseline and after six-months. Normalized FDG-PET images were analyzed using voxel-based SPM5 approaches to determine longitudinal changes, group-by-time interactions and correlations with neuropsychological outcome parameters. Primary global cognitive outcome was determined by analyses of covariance with MMSE and ADAS-cog scores as dependent measures. Both, aMCI and AD subgroups of CGs showed widespread bilateral cortical declines in FDG uptake, while the AD subgroup of IGs showed discrete decline or rather no decline in case of the aMCI subgroup. Group by time analyses revealed strongest attenuation of metabolic decline in the aMCI subgroup of the IGs, involving left anterior temporal pole and anterior cingulate gyrus. However, correlation analyses revealed only weak non-significant associations between increased FDG uptake and improvement in primary or secondary outcome parameters. Concurrently, there was significant improvement in global cognitive status in the aMCI subgroup of the IGs. A six-month cognitive intervention imparted cognitive benefits in patients with aMCI, which were concurrent with an attenuated decline of glucose metabolism in cortical regions affected by neurodegenerative AD.
000136367 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000136367 588__ $$aDataset connected to CrossRef, PubMed,
000136367 650_7 $$00Z5B2CJX4D$$2NLM Chemicals$$aFluorodeoxyglucose F18
000136367 650_2 $$2MeSH$$aAged
000136367 650_2 $$2MeSH$$aAged, 80 and over
000136367 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000136367 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000136367 650_2 $$2MeSH$$aAlzheimer Disease: rehabilitation
000136367 650_2 $$2MeSH$$aAmnesia: complications
000136367 650_2 $$2MeSH$$aBrain Mapping
000136367 650_2 $$2MeSH$$aCerebral Cortex: diagnostic imaging
000136367 650_2 $$2MeSH$$aCerebral Cortex: metabolism
000136367 650_2 $$2MeSH$$aCognitive Behavioral Therapy: methods
000136367 650_2 $$2MeSH$$aCognitive Dysfunction: diagnostic imaging
000136367 650_2 $$2MeSH$$aCognitive Dysfunction: etiology
000136367 650_2 $$2MeSH$$aCognitive Dysfunction: pathology
000136367 650_2 $$2MeSH$$aCognitive Dysfunction: rehabilitation
000136367 650_2 $$2MeSH$$aFemale
000136367 650_2 $$2MeSH$$aFluorodeoxyglucose F18
000136367 650_2 $$2MeSH$$aFollow-Up Studies
000136367 650_2 $$2MeSH$$aHumans
000136367 650_2 $$2MeSH$$aMale
000136367 650_2 $$2MeSH$$aMiddle Aged
000136367 650_2 $$2MeSH$$aNeuropsychological Tests
000136367 650_2 $$2MeSH$$aPositron-Emission Tomography: methods
000136367 650_2 $$2MeSH$$aTreatment Outcome
000136367 7001_ $$0P:(DE-HGF)0$$aBuschert, Verena C$$b1
000136367 7001_ $$0P:(DE-2719)2000026$$aTeipel, Stefan$$b2$$udzne
000136367 7001_ $$0P:(DE-HGF)0$$aFriese, Uwe$$b3
000136367 7001_ $$0P:(DE-HGF)0$$aBuchholz, Hans-Georg$$b4
000136367 7001_ $$0P:(DE-HGF)0$$aDrzezga, Alexander$$b5
000136367 7001_ $$0P:(DE-HGF)0$$aHampel, Harald$$b6
000136367 7001_ $$0P:(DE-HGF)0$$aBartenstein, Peter$$b7
000136367 7001_ $$0P:(DE-HGF)0$$aBuerger, Katharina$$b8
000136367 77318 $$2Crossref$$3journal-article$$a10.3233/jad-2011-0025$$b : IOS Press, 2011-10-04$$ns3$$p337-348$$tJournal of Alzheimer's Disease$$v26$$x1875-8908$$y2011
000136367 773__ $$0PERI:(DE-600)2070772-1$$a10.3233/JAD-2011-0025$$gVol. 26 Suppl 3, no. s3, p. 337 - 348$$ns3$$p337-348$$q26 Suppl 3:s3<337 - 348$$tJournal of Alzheimer's disease$$v26$$x1875-8908$$y2011
000136367 8564_ $$uhttps://pub.dzne.de/record/136367/files/DZNE-2020-02689_Restricted.pdf
000136367 8564_ $$uhttps://pub.dzne.de/record/136367/files/DZNE-2020-02689_Restricted.pdf?subformat=pdfa$$xpdfa
000136367 909CO $$ooai:pub.dzne.de:136367$$pVDB
000136367 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000136367 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000136367 9141_ $$y2011
000136367 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ ALZHEIMERS DIS : 2017
000136367 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136367 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136367 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136367 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000136367 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000136367 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000136367 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136367 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136367 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000136367 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136367 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000136367 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x0
000136367 980__ $$ajournal
000136367 980__ $$aVDB
000136367 980__ $$aI:(DE-2719)1510100
000136367 980__ $$aUNRESTRICTED